CHRONIC ASPERGILLOSIS TREATMENT MARKET ANALYSIS

Chronic Aspergillosis Treatment Market, by Drug Class (Corticosteroids and Anti-fungal Drugs), by Disease Type (Simple Aspergilloma, Chronic Cavitary Pulmonary Aspergillosis, Chronic Fibrosing Pulmonary Aspergillosis, Subacute Invasive Aspergillosis, Allergic Bronchopulmonary Aspergillosis [ABPA], and Severe Asthma With Fungal Sensitization [SAFS]), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Store, and E-commerce), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021
Code : CMI4611
Pages :204
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Chronic Aspergillosis Treatment Market: Restraint

The major factors that are expected to hinder growth of the global chronic aspergillosis treatment market include increasing generic competition and complications associated with drugs used in the treatment of chronic aspergillosis. For instance, in November 2016, Ajanta Pharma, a pharmaceutical company, launched voriconazole tablets in 50-mg and 200-mg doses in the U.S. market. These tablets are the equivalent generic version of Vfend, an antifungal drug from Pfizer. Vfend is used to treat conditions such as invasive aspergillosis, candidemia, and serious infections caused by Scedosporium apiospermum and Fusarium species.

Chronic Aspergillosis Treatment Market Report Snapshots